HCPLive reported on Thursday, October 22, 2026, that intravenous thrombolysis does not modify endovascular therapy in strokes caused by medium vessel occlusion (MDVO). The finding, as summarized by the outlet, concerns whether giving clot-dissolving medication through a vein changes the use of endovascular treatment, which is delivered directly inside the blood vessel.
The report frames the two approaches as separate parts of care rather than one reshaping the other. According to HCPLive, the intravenous treatment leaves endovascular therapy unaffected in this stroke category. The summary did not include patient numbers, trial names, or outcome figures.
The distinction matters because medium vessel occlusions sit between the large vessels typically addressed with endovascular procedures and the smaller ones. Whether a patient first receives intravenous thrombolysis has been an open question in stroke care, and the HCPLive report indicates it does not dictate the endovascular decision for this group.
The source material did not specify the study design, the institutions involved, or where the findings were presented or published. It also did not describe any safety results or comparisons between treated and untreated patients.
Watch for the full study details and any guidance from stroke bodies on how intravenous thrombolysis and endovascular therapy should be sequenced for medium vessel occlusion patients.
